BVS vs NVCR vs OSUR vs ATRC vs LNTH

For growth investors, AtriCure, Inc.

(ATRC) is the stronger pick with 14. 9% revenue growth year-over-year, versus -38. 1% for OraSure Technologies, Inc. (OSUR). Bioventus Inc. (BVS) offers the better valuation at 25. 8x trailing P/E (11. 0x forward), making it the more compelling value choice. Analysts rate Bioventus Inc. (BVS) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Bioventus Inc.

(BVS) is the cheapest at 25. 8x versus Lantheus Holdings, Inc. at 29. 1x. On forward P/E, Bioventus Inc. is actually cheaper at 11. 0x.

Over the past 5 years, Lantheus Holdings, Inc.

(LNTH) delivered a total return of +303. 8%, compared to -91. 6% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: LNTH returned +49. 9% versus BVS's -55. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Lantheus Holdings, Inc.

(LNTH) is the lower-risk stock at 0. 53β versus NovoCure Limited's 2. 24β — meaning NVCR is approximately 322% more volatile than LNTH relative to the S&P 500. On balance sheet safety, Lantheus Holdings, Inc. (LNTH) carries a lower debt/equity ratio of 0% versus 136% for Bioventus Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AtriCure, Inc.

(ATRC) is pulling ahead at 14. 9% versus -38. 1% for OraSure Technologies, Inc. (OSUR). On earnings-per-share growth, the picture is similar: Bioventus Inc. grew EPS 163. 5% year-over-year, compared to -261. 5% for OraSure Technologies, Inc.. Over a 3-year CAGR, LNTH leads at 18. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Lantheus Holdings, Inc.

(LNTH) is the more profitable company, earning 15. 2% net margin versus -59. 8% for OraSure Technologies, Inc. — meaning it keeps 15. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LNTH leads at 20. 2% versus -59. 2% for OSUR. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Bioventus Inc.

(BVS) trades at 11. 0x forward P/E versus 737. 9x for AtriCure, Inc. — 726. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 96. 6% to $33. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Lantheus Holdings, Inc.

(LNTH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 53)). NovoCure Limited (NVCR) carries a higher beta of 2. 24 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LNTH: +49. 9%, NVCR: +53. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.